Our Company listed on the Australian Securities Exchange (ASX) in February 2020 under ticker code EMD. The year of COVID-19, which elevated the importance of purposeful innovation in healthcare – at hyper speed.
Thankfully, innovation is in our DNA. We navigated the pandemic (and beyond) with great care, establishing world-class learning healthcare models in our clinics; testing new diagnostic technologies; and focusing, intently, on novel drug development too.
Now – armed with a deep understanding of unmet patient needs, engagement with healthcare regulators, and clinical care models founded on evidence, first – we are making a profound impact on a drastically underserved vertical of the healthcare system. Mental health.
The human brain is the most complex organ in our bodies. It interprets our senses, initiates movement, controls our behaviour, and dictates how we process and share knowledge too.
Unsurprisingly, it is at the centre of a deeply complicated area of healthcare. It always has been. For centuries, mental health has been devoid of purposeful investment – resulting in a devastating pattern of underserved patient needs, which inevitably impact quality and length of life.
Our research and development (R&D) pipeline at Emyria is focused on changing that. Our lead program is evaluating MDMA-Assisted Therapy for Post-Traumatic Stress Disorder (PTSD).
We are also advancing the MDMA molecule itself and refining its interaction with primary neurotransmitters like serotonin and dopamine. A new compound with enhanced selectivity may elevate the efficacy of drug-assisted mental health therapies and broaden its potential applications across a spectrum of conditions.
Our goal? To nurture the next generation of healthier minds.
What sets our Company and its collaborators apart, is a deep commitment to making tangible inroads to address the mental health crisis – through focused research, measured investment and commercially-scalable healthcare solutions.
We are on track to become world-leaders in a promising new mental healthcare market, through our efforts to test MDMA and psilocybin for the treatment of conditions like post traumatic stress disorder (PTSD) and depression.
We are also developing novel MDMA-like compounds and exploring their potential in select neurological conditions like Parkinson’s disease, and more.
The societal and economic motivation to address mental health is real. Over 2 in 5 Australians experience a mental disorder at some time in their life. 1 in 5 Australians had a mental disorder in the past 12 months. Demand is unprecedented but, in Australia right now, 1 in 3 psychologists have closed books. We need entirely new solutions.
Emyria has the essential ingredients – purpose-built clinics, tailored technology infrastructure and the right team – to provide psychedelic treatments within the regulatory framework. We have a clear plan to scale our clinics with strong commercial foundations too, which will create immediate patient impact and real value for our investors.
Eager to learn more?
All medicines carry risks and specialist prescribers, such as registered psychiatrists, are best placed to assess the suitability of a new medication against a patient’s individual circumstances and medical history before proceeding. Adverse effects of MDMA include high blood pressure, increased pulse rate, faintness, and panic attacks, and in some rare cases it can cause loss of consciousness or trigger seizures. Other side effects include involuntary jaw clenching, decreased appetite, restless legs, nausea, headache, sweating and muscle/joint stiffness. These effects are unlikely at low doses in the treatment regimens used in psychedelic-assisted psychotherapy while appropriately managed in a controlled environment with direct medical supervision.